Harry P. Erba

Harry P. Erba

Oncology | Hematology
2400 Pratt St
Durham, NC 27705

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 139 publications

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

Journal: Future oncology (London, England)
Published: July 11, 2026

Real-World Outcomes in First-Line Venetoclax-Based Therapy in Patients With AML Ineligible for Intensive Chemotherapy: A Single Center Study.

Real-World Outcomes in First-Line Venetoclax-Based Therapy in Patients With AML Ineligible for Intensive Chemotherapy: A Single Center Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 22, 2026

Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".

Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".

Journal: Haematologica
Published: April 01, 2026

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Journal: Blood
Published: March 18, 2026

Personalized measurable residual disease assays for acute myeloid leukemia guided by whole-genome sequencing.

Personalized measurable residual disease assays for acute myeloid leukemia guided by whole-genome sequencing.

Journal: Haematologica
Published: February 12, 2026

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 11, 2026

Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia.

Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia.

Journal: medRxiv : the preprint server for health sciences
Published: February 06, 2026

Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.

Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.

Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025

Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML.

Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML.

Journal: Blood neoplasia
Published: November 21, 2025

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 25, 2025

Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Journal: Blood advances
Published: July 11, 2025

Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Journal: Blood advances
Published: July 11, 2025
Showing 1-12 of 139

Last Updated: 09/26/2026